# The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control Study

> **NCT06504420** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 70 (estimated)

## Conditions studied

- Primary Antiphospholipid Syndrome

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06504420
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-15
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06504420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06504420, "The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control Study". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06504420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*